NCT06509009 2025-09-19
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
Clinical Trials
12 trialsNCT07070479 2025-09-18
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06912711 2025-05-21
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04223024 2025-03-05
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT03025958 2024-05-06
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2 Completed
NCT06259721 2024-03-07
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Phase 2 Recruiting
NCT03708822 2024-01-18
Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04508816 2022-04-04
Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
Fudan University
Phase 2 Completed
NCT03915132 2021-01-29
Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma
ChineseAMS
Phase 2 Unknown
NCT03557112 2018-11-02
By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC
Guiyang Medical University
Phase 2 Unknown
NCT03666221 2018-09-11
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Phase 2 Unknown
NCT01616849 2015-09-22
Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Completed